5-phenyl-1-{5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]pyridin-2-yl}imidazolidin-2-one | 2170454-96-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 5-phenyl-1-{5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]pyridin-2-yl}imidazolidin-2-one
• 英文别名: US11066396, Example 338；5-phenyl-1-[5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]pyridin-2-yl]imidazolidin-2-one
• CAS: 2170454-96-1
• 化学式: C₁₇H₁₂F₃N₅O₂
• 分子量: 375.31
• InChiKey: RPRALHBVIACJEU-UHFFFAOYSA-N

物化性质

• 密度：
  1.432±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  84.2
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• [EN] 3-ARYL AND HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS<br/>[FR] 5-TRIFLUOROMÉTHYL-OXADIAZOLES SUBSTITUÉS EN 3-ARYLE ET HÉTÉROARYLE EN TANT QU'INHIBITEURS DE L'HISTONE DÉSACÉTYLASE 6 (HDAC6)
  申请人：MERCK SHARP & DOHME

  公开号：WO2017222951A1

  公开（公告）日：2017-12-28

  The present invention is directed to substituted 5-trifluoromethyl oxadiazole compounds of generic formula (I) or a pharmaceutically acceptable salt thereof. In particular, the invention is directed to a class of aryl and heteroaryl substituted 5-trifluoromethyl oxadiazole compounds of formula I which may be useful as HDAC6 inhibitors for treating cellular proliferative diseases, including cancer, neurodegenerative diseases, such as schizophrenia and stroke, as well as other diseases.

  本发明涉及通式（I）的取代5-三氟甲基噁二唑化合物或其药学上可接受的盐。具体而言，本发明涉及一类芳基和杂环芳基取代的通式I的5-三氟甲基噁二唑化合物，可能作为HDAC6抑制剂用于治疗细胞增殖性疾病，包括癌症、神经退行性疾病（如精神分裂症和中风）以及其他疾病。
• 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：US11066396B2

  公开（公告）日：2021-07-20

  The present invention is directed to substituted 5-trifluoromethyl oxadiazole compounds of generic formula (I) or a pharmaceutically acceptable salt thereof. In particular, the invention is directed to a class of aryl and heteroaryl substituted 5-trifluoromethyl oxadiazole compounds of formula I which may be useful as HDAC6 inhibitors for treating cellular proliferative diseases, including cancer, neurodegenerative diseases, such as schizophrenia and stroke, as well as other diseases.

  本发明涉及通式(I)的取代的5-三氟甲基噁二唑化合物或其药学上可接受的盐。特别是，本发明涉及一类式 I 的芳基和杂芳基取代的 5-三氟甲基噁二唑化合物，其可作为 HDAC6 抑制剂用于治疗细胞增殖性疾病，包括癌症、神经退行性疾病（如精神分裂症和中风）以及其他疾病。
• 3-ARYL AND HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3475275A1

  公开（公告）日：2019-05-01
• 3-ARYL- HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONEDEACETYLASE 6 (HDAC6) INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20190185462A1

  公开（公告）日：2019-06-20

  The present invention is directed to substituted 5-trifluoromethyl oxadiazole compounds of generic formula (I) or a pharmaceutically acceptable salt thereof. In particular, the invention is directed to a class of aryl and heteroaryl substituted 5-trifluoromethyl oxadiazole compounds of formula I which may be useful as HDAC6 inhibitors for treating cellular proliferative diseases, including cancer, neurodegenerative diseases, such as schizophrenia and stroke, as well as other diseases.